Vonoprazan-Fumarate-TAK-438-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVonoprazan FumarateCat. No.: HY-15295CAS No.: 1260141-27-2Synonyms: TAK-438分式: CHFNOS分量: 461.46作靶點(diǎn): Proton Pump作通路: Membrane Transporter/Ion Channel儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn)

2、DMSO : 50 mg/mL (108.35 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.1670 mL 10.8352 mL 21.6704 mL5 mM 0.4334 mL 2.1670 mL 4.3341 mL10 mM 0.2167 mL 1.0835 mL 2.1670 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，

3、體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.42 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.42 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oil

4、1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (5.42 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Vonoprazan Fumarate (TAK-438)有種服活性的 鉀競(jìng)爭(zhēng)性酸阻斷劑，抑制 H+, K+-ATPase的 IC50 值為19 nM。戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Br J Clin Pharmacol. 2019 Mar 7. Drug Metab Dispos. 2016 Oct;44(10):1543-9.See more customer

5、validations on HYPERLINK / www.MedChemEREFERENCES1. Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456.2. Hor

6、i Y, et al. 1-5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl-N-methylmethanamine monofumarate (TAK-438), a novel andpotent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238.3. Hori Y, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole inanimals. J Pharmacol Exp Ther, 2011, 337(3), 797-804.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only